LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Home・Aktien・Cogent Biosciences Inc

Cogent Biosciences Inc

Geschlossen

38.64 -1.78

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

38.42

Max

38.88

Schlüsselkennzahlen
By Trading Economics
Einkommen	-22M -102M
EPS	-0.5
Angestellte	258
EBITDA	-30M -109M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+34.31% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	5. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	408M 6B
Vorheriger Eröffnungskurs	40.42
Vorheriger Schlusskurs	38.64

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

4.88 / 5.87 Unterstützung & Widerstand

Cogent Biosciences Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

27. Feb. 2026, 23:53 UTC

Heiße Aktien

Stocks to Watch: Aardvark Therapeutics, Blue Moon Metals

27. Feb. 2026, 22:23 UTC

Akquisitionen, Fusionen, Übernahmen

Blue Moon Metals To Acquire Apex Germanium Mine From Teck Subsidiary

1. März 2026, 00:00 UTC

Wichtige Nachrichtenereignisse

Trump's War on Iran Threatens to Drive Up Oil Prices and Inflation -- WSJ

28. Feb. 2026, 21:36 UTC

Ergebnisse

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28. Feb. 2026, 21:27 UTC

Wichtige Nachrichtenereignisse

Iran Strikes Could Make Fed Rate Cuts Even Less Likely -- Barrons.com

28. Feb. 2026, 15:20 UTC

Ergebnisse

Berkshire's Abel Pledges to Follow Buffett's 'Framework' in First Shareholder Letter -- 2nd Update

28. Feb. 2026, 14:43 UTC

Ergebnisse

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28. Feb. 2026, 14:40 UTC

Wichtige Nachrichtenereignisse

What Defense Stocks Stand to Gain -- and Lose -- From the U.S. Attacks on Iran -- Barrons.com

28. Feb. 2026, 14:38 UTC

Ergebnisse

Berkshire's Abel Pledges to Follow Buffett's 'Framework' in First Shareholder Letter -- Update

28. Feb. 2026, 13:51 UTC

Wichtige Nachrichtenereignisse

What Defense Stocks Stand to Gain--and Lose--From the US Attacks on Iran -- Barrons.com

28. Feb. 2026, 13:47 UTC

Ergebnisse

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28. Feb. 2026, 13:44 UTC

Ergebnisse

Berkshire Hathaway Earnings Slip on Decline in Insurance Results -- WSJ

28. Feb. 2026, 13:14 UTC

Ergebnisse

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28. Feb. 2026, 12:41 UTC

Wichtige Nachrichtenereignisse

Iran's Rulers Face an All-Out Battle for Survival -- Barrons.com

28. Feb. 2026, 10:30 UTC

Akquisitionen, Fusionen, Übernahmen

All The Ways Netflix Actually Won Even Though It Lost Warner -- Heard on the Street -- WSJ

28. Feb. 2026, 02:32 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Calpers Buys Into Hot Chip And Quantum Stocks -- Barrons.com

28. Feb. 2026, 02:00 UTC

Akquisitionen, Fusionen, Übernahmen

Six Months, 9 Offers and $81 Billion. How Hollywood's Nasty Takeover Was Won. -- WSJ

28. Feb. 2026, 02:00 UTC

Akquisitionen, Fusionen, Übernahmen

Six Months, 9 Offers and $81 Billion. How -2-

28. Feb. 2026, 00:01 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Issuing $47 Billion of Equity at Big Premium to Stock Price for Warner Bros. Deal -- Barrons.com

27. Feb. 2026, 23:46 UTC

Akquisitionen, Fusionen, Übernahmen

Netflix Walks Away a Winner After Losing Warner Bros. to Paramount -- Barrons.com

27. Feb. 2026, 23:33 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Issuing $47 Billion of Equity at Nearly 20% Premium to Current Stock Price -- Barrons.com

27. Feb. 2026, 21:50 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Tech, Media & Telecom Roundup: Market Talk

27. Feb. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

27. Feb. 2026, 21:30 UTC

Ergebnisse

Solventum Beat Wall Street Earnings Estimates. The Stock Falls. -- Barrons.com

27. Feb. 2026, 21:30 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Warner Terminates Netflix Deal, Ending Monthslong Saga -- Market Talk

27. Feb. 2026, 21:20 UTC

Akquisitionen, Fusionen, Übernahmen

Blue Moon Metals to Buy Apex Germanium and Gallium Mine From Teck >BMM

27. Feb. 2026, 21:17 UTC

Ergebnisse

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

27. Feb. 2026, 21:10 UTC

Akquisitionen, Fusionen, Übernahmen

Blue Moon Metals Evaluating Options for a New Processing Line at Springer Complex to Process the Apex Material

27. Feb. 2026, 21:09 UTC

Akquisitionen, Fusionen, Übernahmen

Blue Moon Metals to Acquire the Apex Germanium and Gallium Mine From Teck

27. Feb. 2026, 21:00 UTC

Ergebnisse

Nike: 3Q Results to Be Released March 31 to Accommodate for Several Holidays >NKE

Peer-Vergleich

Kursveränderung

Cogent Biosciences Inc Prognose

Kursziel

By TipRanks

34.31% Vorteil

12-Monats-Prognose

Durchschnitt 52.18 USD 34.31%

Hoch 67 USD

Tief 35 USD

Basierend auf 12 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Cogent Biosciences Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

12 ratings

Buy

Halten

Sell

Basierend auf 12 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Cogent Biosciences Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

4.88 / 5.87Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.